Drug updated on 11/15/2023
| Dosage Form | Tablet (oral: 4.5 mg, 9 mg, 13.5 mg) |
| Drug Class | Kinase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
- For the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Pemazyre (pemigatinib) Prescribing Information. | 2023 | Incyte Corporation, Wilmington, DE |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Clinical and pharmacoeconomic combined report: pemigatinib (Pemazyre). | 2022 | CADTH |
| Assessment report: Pemazyre. | 2021 | EMA |